Clinical Trials Logo

Colorectal Cancer clinical trials

View clinical trials related to Colorectal Cancer.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT03914170 Completed - Colorectal Cancer Clinical Trials

Folfirinox + Cetuximab Chemotherapy, in First Line, With Wild RAS and According to BRAF Status in Metastatic Colorectal Cancer

Start date: April 1, 2017
Study type: Observational

This retrospective study, will evaluate patient outcomes after triplet chemotherapy (FOLFIRINOX) (5 Fluorouracil + oxaliplatin + irinotecan) plus cetuximab 1st line treatment focusing on efficacy and safety in a RAS (KRAS, NRAS (neuroblastoma rat sarcoma viral oncogene homolog) wild-type metastatic colorectal cancer population, and according to BRAF (murine sarcoma viral oncogene homolog B) status and primary tumor location.

NCT ID: NCT03889171 Completed - Breast Cancer Clinical Trials

Comparison to Psychological, Medical and Emotional Influencing Communication and Achievement Factors to Oncogenetics Tests

Start date: August 2012
Study type: Observational

The purpose of the study was to analyze the psychological and emotional determinants of domestic dissemination of information about genetic risk of cancer and to compare the level of diffusion syndromes in breast/ ovarian cancer ( BRCA1 / BRCA2) and colon/endometrial ( HNPCC )

NCT ID: NCT03888638 Completed - Colorectal Cancer Clinical Trials

The Role of Tumor-associated Macrophages in Colorectal Liver Metastases

Start date: January 1, 2015
Study type: Observational

Colorectal cancer is a major cause of mortality worldwide. Most patients develop colorectal liver metastases (CLM), and for such patients hepatectomy combined with chemotherapy may be curative. Nevertheless, in the era of precision medicine there is a critical need of prognostic markers to cope with the heterogeneity of CLM patients. Tumor-associated macrophages (TAMs) pave the way to tissue invasion and intravasation providing a nurturing microenvironment formetastases. The quantification of immune landscape of tumors has provided novel prognostic indicators of cancer progression, and the quantification of TAMs might explain the heterogeneity of CLM patients. Here, we will investigate the development of a new diagnostic tool based on TAMs with the aim to define the causative role of TAMs in CLM patients. This will open new clinical scenarios both for the diagnosis, therapy and prognosis, leading to the refinement of the therapeutic output in a personalized medicine perspective.

NCT ID: NCT03819920 Completed - Colorectal Cancer Clinical Trials

Does Knowing One's Estimated Colorectal Cancer Risk Influence Screening Behavior?

Start date: October 6, 2015
Phase: N/A
Study type: Interventional

This study is designed to examine the impact of telephone-based colorectal cancer risk assessment on colorectal screening attitudes and behavior among previously unscreened adults ages 50 to 75.

NCT ID: NCT03787537 Completed - Colorectal Cancer Clinical Trials

Nutritional Status and Nutrient Supply in Hospitalised Surgical Patients

Start date: August 1, 2017
Study type: Observational

Prospective single arm, single center observational study to assess the nutritional status and the nutrient supply during hospitalization for elective gastrointestinal surgery.

NCT ID: NCT03782428 Completed - Colorectal Cancer Clinical Trials

An Evaluation of Probiotic in the Clinical Course of Patients With Colorectal Cancer

Start date: August 26, 2016
Phase: N/A
Study type: Interventional

Colorectal cancer (CRC) is the most common cancer for men and the second most common for women. Several studies have shown that gut microbiome may play a role in triggering intestinal inflammation that leads to the development of CRC. Gut microbiome is the collection of microorganisms that inhabit the gut. Therefore, manipulation of the gut microbiome via administration of probiotics may potentially improve the health and nutritional status in patients with CRC. The aims of this study are to investigate the role of probiotic functional foods in reducing CRC-related inflammatory markers and symptom alleviation.Participants will be needed to complete an information details form which includes information on age, medical history, background details and diet. Participants are required to consume the investigational product twice daily for six months. Blood samples will be collected prior to surgery and at 6th months post product consumption. These blood samples will be processed and analysed.

NCT ID: NCT03717519 Completed - Colorectal Cancer Clinical Trials

Elevated Platelet Count as Prognostic Factor in Colorectal Cancer With Synchronous Liver Metastases

Start date: January 1, 2018
Study type: Observational

Colorectal cancer (CRC) is the third most common malignancy worldwide and is often metastatic at diagnosis. Despite progresses in surgical techniques and the introduction of novel chemotherapy regimens, many patients still suffer from a poor prognosis. It is therefore of utmost importance to identify prognostic markers that may improve selection of patients. In recent years several studies demonstrated that preoperative blood tests as platelet count or neuthophil-to-lymphocyte ratio could be prognostic factors in CRC as well as other malignancies. The aim of this study was to evaluate the role of preoperative platelet count (PC) in patients with synchronous colorectal liver metastases.

NCT ID: NCT03698253 Completed - Colorectal Cancer Clinical Trials

Metastatic Colorectal Cancer Treated With Regorafenib and FOLFIRI

Start date: October 1, 2013
Phase: N/A
Study type: Interventional

The survey is a retrospective study to evaluate the prognotic value of EGFR expression, KRAS mutations and tumor sideness in patients with metastatic colorectal cancer treated with regorafenib and FOLFIRI as a third- or fourth-line setting.

NCT ID: NCT03642652 Completed - Colorectal Cancer Clinical Trials

SMS Reminders for Positive FOBT Follow-up

Start date: April 1, 2016
Phase: N/A
Study type: Interventional

A randomized controlled trial to examine the effect of 3 mobile telephone text message reminders on followup colonoscopy 120 days after a positive fecal occult blood test among Meuhedet members aged 50-74 who tested positive in 2016.

NCT ID: NCT03640572 Completed - Colorectal Cancer Clinical Trials

Disseminated Tumour Cells (DTC) in Left Sided Colorectal Cancer (LSCC).

Start date: June 1, 2007
Study type: Observational

Two metaanalyses of studies on the prognostic significance of circulating cancer cells in colorectal cancer indicated, that the presence of circulating tumour cells (CTC) in the peripheral blood is the negative prognostic factor. However there is no sufficient evidence that disseminated tumour cells (DTC) in the bone marrow of the colorectal cancer patients influence the prognosis. There is the evidence that right-sided and left- sided cancers may have different biology and different prognosis. Therefore in this study the investigators concentrated on the left colon and rectum locations with the locally advanced cancer being the main area of interest. The aim of this study was to analyse the relation of DTC with the tumor characteristics, cancer progression and survival in left sided colorectal cancer.